A detailed history of Srs Capital Advisors, Inc. transactions in Veracyte, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 19 shares of VCYT stock, worth $743. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19
Previous 34 44.12%
Holding current value
$743
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$21.0 - $35.25 $315 - $528
-15 Reduced 44.12%
19 $0
Q2 2024

Aug 06, 2024

BUY
$18.86 - $23.55 $18 - $23
1 Added 3.03%
34 $0
Q4 2023

Feb 06, 2024

BUY
$19.72 - $28.68 $177 - $258
9 Added 37.5%
33 $0
Q4 2022

Feb 24, 2023

BUY
$15.31 - $29.94 $367 - $718
24 New
24 $0
Q2 2022

Aug 22, 2022

SELL
$15.45 - $29.52 $309 - $590
-20 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$36.09 - $53.79 $721 - $1,075
20 New
20 $1,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.8B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Srs Capital Advisors, Inc. Portfolio

Follow Srs Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Srs Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Srs Capital Advisors, Inc. with notifications on news.